|
rs11979158
|
|
Glioma
|
A |
0.850 |
GeneticVariation
|
GWASCAT |
Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21.
|
29743610 |
2018 |
|
rs11979158
|
|
Glioma
|
A |
0.850 |
GeneticVariation
|
GWASCAT |
Using these data, we demonstrate two statistically independent associations between glioma and rs11979158 and rs2252586, at 7p11.2 which encompasses the EGFR gene (population-corrected statistics, P(c) = 7.72 × 10(-8) and 2.09 × 10(-8), respectively).
|
21531791 |
2011 |
|
rs11979158
|
|
Glioma
|
A |
0.850 |
GeneticVariation
|
GWASDB |
Using these data, we demonstrate two statistically independent associations between glioma and rs11979158 and rs2252586, at 7p11.2 which encompasses the EGFR gene (population-corrected statistics, P(c) = 7.72 × 10(-8) and 2.09 × 10(-8), respectively).
|
21531791 |
2011 |
|
rs1057519847
|
|
Non-Small Cell Lung Carcinoma
|
AG |
0.800 |
GeneticVariation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
rs1057519848
|
|
Non-Small Cell Lung Carcinoma
|
GT |
0.800 |
GeneticVariation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
rs121434568
|
|
Non-Small Cell Lung Carcinoma
|
A |
0.800 |
GeneticVariation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
rs606231253
|
|
INFLAMMATORY SKIN AND BOWEL DISEASE, NEONATAL, 2
|
A |
0.800 |
CausalMutation
|
CLINVAR |
|
|
|
|
rs606231253
|
|
INFLAMMATORY SKIN AND BOWEL DISEASE, NEONATAL, 2
|
|
0.800 |
GeneticVariation
|
UNIPROT |
|
|
|
|
rs121913444
|
|
Non-Small Cell Lung Carcinoma
|
A |
0.750 |
CausalMutation
|
CLINVAR |
MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib.
|
23102728 |
2013 |
|
rs121913444
|
|
Non-Small Cell Lung Carcinoma
|
A |
0.750 |
CausalMutation
|
CLINVAR |
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
|
22753918 |
2012 |
|
rs121913444
|
|
Non-Small Cell Lung Carcinoma
|
A |
0.750 |
CausalMutation
|
CLINVAR |
Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer.
|
19922469 |
2010 |
|
rs121913444
|
|
Non-Small Cell Lung Carcinoma
|
A |
0.750 |
CausalMutation
|
CLINVAR |
"EGF receptor gene mutations are common in lung cancers from ""never smokers"" and are associated with sensitivity of tumors to gefitinib and erlotinib."
|
15329413 |
2004 |
|
rs121913444
|
|
Non-Small Cell Lung Carcinoma
|
A |
0.750 |
CausalMutation
|
CLINVAR |
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
|
15118073 |
2004 |
|
rs121913444
|
|
Non-Small Cell Lung Carcinoma
|
A |
0.750 |
CausalMutation
|
CLINVAR |
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
|
15118125 |
2004 |
|
rs28929495
|
|
Non-Small Cell Lung Carcinoma
|
T |
0.750 |
CausalMutation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
rs28929495
|
|
Non-Small Cell Lung Carcinoma
|
T |
0.750 |
CausalMutation
|
CLINVAR |
MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib.
|
23102728 |
2013 |
|
rs28929495
|
|
Non-Small Cell Lung Carcinoma
|
T |
0.750 |
CausalMutation
|
CLINVAR |
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
|
22753918 |
2012 |
|
rs28929495
|
|
Non-Small Cell Lung Carcinoma
|
T |
0.750 |
CausalMutation
|
CLINVAR |
Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.
|
21841502 |
2011 |
|
rs28929495
|
|
Non-Small Cell Lung Carcinoma
|
T |
0.750 |
CausalMutation
|
CLINVAR |
Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.
|
19536777 |
2010 |
|
rs28929495
|
|
Non-Small Cell Lung Carcinoma
|
T |
0.750 |
CausalMutation
|
CLINVAR |
Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer.
|
19922469 |
2010 |
|
rs28929495
|
|
Non-Small Cell Lung Carcinoma
|
T |
0.750 |
CausalMutation
|
CLINVAR |
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.
|
20479403 |
2010 |
|
rs28929495
|
|
Non-Small Cell Lung Carcinoma
|
T |
0.750 |
CausalMutation
|
CLINVAR |
Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations.
|
19671738 |
2009 |
|
rs28929495
|
|
Non-Small Cell Lung Carcinoma
|
T |
0.750 |
CausalMutation
|
CLINVAR |
Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
|
18199554 |
2008 |
|
rs28929495
|
|
Non-Small Cell Lung Carcinoma
|
T |
0.750 |
CausalMutation
|
CLINVAR |
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
|
15710947 |
2005 |
|
rs28929495
|
|
Non-Small Cell Lung Carcinoma
|
T |
0.750 |
CausalMutation
|
CLINVAR |
Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.
|
16115929 |
2005 |